Amgen's $10.35 Billion Trading Volume Lands 75th Amid Stock Decline

On May 14, 2025, Amgen's trading volume reached $10.35 billion, marking a 43.6% increase from the previous day, placing it 75th in the day's stock market rankings. Amgen's stock price fell by 3.02%, marking the second consecutive day of decline, with a total decrease of 4.54% over the past two days.

Amgen's stock price has been under pressure due to concerns over the company's pipeline and regulatory hurdles. The company's recent clinical trial results for its lead drug candidate have been disappointing, raising questions about its efficacy and safety. Additionally, the FDA has delayed its decision on the approval of another key drug, adding to investor uncertainty.

Despite these challenges, some analysts remain optimistic about Amgen's long-term prospects. The company has a strong portfolio of approved drugs and a robust pipeline of potential blockbusters. Furthermore, Amgen's recent acquisition of a smaller biotech firm has expanded its capabilities in gene therapy, a rapidly growing field with significant potential.

Investors will be closely watching Amgen's upcoming earnings report for any signs of improvement in its financial performance. The company is expected to report strong revenue growth driven by its approved drugs, but concerns over its pipeline and regulatory hurdles may continue to weigh on its stock price.